Our portfolio of value-added generic medicines primarily addresses problems of patients suffering from diseases in the gastrointestinal and hepatobiliary tracts, but our product range extends to patient care in cardiology, psychiatry, urology and other conditions. By maintaining a continuous focus on identifying novel treatments and indications, we are committed to bringing innovative and affordable medicines to patients.
The gastrointestinal tract performs a large number of far-reaching, sophisticated processes that are also somewhat contradictory: it is responsible for taking in and processing food, absorbing nutrients, obtaining energy, protecting the body against infiltration and the effects of external pathogenic noxae, and excreting undigested remnants and products of metabolism. We know that a properly functioning GIT is a basic prerequisite to maintain the body’s homeostasis – and thus a person’s health and general wellbeing. This is the primary reason why PRO.MED.CS Praha a. s. set out on the path to help patients suffering from diseases of the digestive tract.
We discovered the first building block for treatment in the bioorganic molecule that opened our understanding of hepatobiliary system diseases and launched pioneering research into the pathophysiology of hepatic metabolism in the human body. The knowledge we have allows us to continually innovate and cover areas with unmet clinical need. What drives us are the need and opportunity to help patients and their families live to the fullest every day.
There are few fields of medicine that have seen such rapid progress in recent decades as hepatology. Because of this, an ever-increasing number of patients can enjoy a significant extension and improvement in their quality of life – or possibly even a total cure for their condition. In spite of these important advances, liver disease remains a major health burden in the current population. In Europe alone, tens of millions of patients suffer from a serious chronic liver disease.
A diagnosis of a rare disease, such as primary biliary cholangitis (PBC), may represent a turning point in a person’s life. This life-shortening illness launches a chronic autoimmune inflammatory process associated with liver cholestasis. Unless it is adequately treated, the final phase culminates in biliary cirrhosis. PRO.MED.CS Praha a. s. is the leader in the treatment of PBC. The objective of ursodeoxycholic acid (UDCA) pharmacotherapy is to prevent progression to the terminal phase, alleviate associated symptoms and improve the quality of patients’ lives.
Non-alcoholic fatty liver disease (NAFLD) represents a fundamental medical problem worldwide. Research is underway now that is aimed at finding effective, safe therapy. We are a part of this effort, and we are contributing to innovations focused on tackling NAFLD.
Many people around the world suffer from chronic problems with constipation, diarrhoea, abdominal pain and flatulence, and they do not realise that effective solutions do exist. Although functional gastrointestinal disorders such as irritable bowel disease or functional dyspepsia do not directly threaten patients’ lives, they can have a serious impact on their quality of life. For this group of patients, our products represent an effective therapeutic alternative which allows them to return to active life.
The medicinal products in our portfolio have strictly defined indications that are specific to individual countries. The information listed for each product complies with local legislation. Product availability, names, and indications for use may also vary from country to country. The list of medicines and active substances below is regularly updated.
| AMBROSAN | ambroxoli hydrochloridum |
| AMILIA | amisulpridum |
| BETAXOLOL PMCS | betaxololi hydrochloridum |
| BISOPROLOL PMCS | bisoprololi fumaras |
| CIFLOXINAL | ciprofloxacini hydrochloridum monohydricum |
| COMBISO | bisoprololi fumaras, hydrochlorothiazidum |
| CORSIM | simvastatinum |
| FAMOSAN | famotidinum |
| GODASAL | acidum acetylsalicylicum, glycinum |
| INDAP | indapamidum |
| INDAPAMID PMCS | indapamidum |
| ITOPRID PMCS | itopridi hydrochloridum |
| METEOSPASMYL | alverini citras, simeticonum |
| MONOSAN | isosorbidi mononitras |
| NITRESAN | nitrendipinum |
| PERINDOPRIL PMCS | perindoprilum erbuminum |
| PROKANAZOL | itraconazolum |
| PROPANORM | propafenoni hydrochloridum |
| PROSULPIN | sulpiridum |
| PROVIRSAN | aciclovirum |
| REBAGIT | rebamipide |
| RILUZOL PMCS | riluzolum |
| RIVOCOR | bisoprololi fumaras |
| RIVODARON | amiodaroni hydrochloridum |
| SALOZINAL | mesalazinum |
| SOLIFENACIN PMCS | solifenacini succinas |
| SPASMED | trospii chloridum |
| TERFIMED | terbinafini hydrochloridum |
| TIAPRID PMCS | tiapridi hydrochloridum |
| URSOSAN | acidum ursodeoxycholicum |
| URSOSAN FORTE | acidum ursodeoxycholicum |
| WARFARIN PMCS | warfarinum natricum clathratum |
| YLPIO | telmisartanum, indapamidum |
We’re active in more than thirty countries around the world. To find out more about the availability of medicines in a particular country, select it from the list.
We’re pleased that we have been able to expand our operations, allowing us to help an ever-growing number of people around the world. During the COVID-19 pandemic we became active in Malaysia, and we are continuing to make inroads this year. Preparations are underway for the launch of our first medicinal product on the UAE market.